Nextremity Solutions Inc. 05.17.16
An article in The Journal of Foot and Ankle Surgery entitled, “Dual-Component Intramedullary Implant Versus Kirschner Wire for Proximal Interphalangeal Joint Fusion: A Randomized Controlled Clinical Trial,” shows significant advantages of using the Nextra Hammertoe Correction System as opposed to using traditional Kirschner Wires (K-wires) for the treatment of hammertoe deformity.
The Nextra device is a two-piece implant developed by Nextremity Solutions Inc., a pure-play foot and ankle orthopedic device firm located in Warsaw, Ind. The product differs from K-wires by achieving more than a five-fold higher rate of bone fusion. Additionally, the Nextra implant exhibited an 84 percent fusion rate, compared to just 16 percent with K-wires.
“Some of the issues with the utilization of K-wires in hammertoe surgery are a lack of fusion, lack of rotational stability, risk of infection with post-operative K-Wire exposure, and poor patient satisfaction. According to the study, patients with the Nextra implant not only had drastic improvements in fusion rates but also experienced greater pain relief, a decrease in disability and an increase in activity levels. Simply put, the Nextra patients had greater patient satisfaction outcomes. These results help redefine the standard of care for hammertoe patients,” said Mike Coon, executive director of sales and marketing for Nextremity Solutions.
“This study is a great example of our commitment to proving the clinical efficacy and benefits of our products and technology. Nextremity Solutions will continue to work with our surgeon partners to develop innovative solutions with improved and proven clinical outcomes,” added Ryan Schlotterback, executive director of product development for Nextremity Solutions. “We are steadfast in our belief that the foot and ankle market is primed for continued advancements that lead to better surgical outcomes and patient satisfaction.”
The surgeons involved in the randomized controlled clinical trial are Richard M. Jay, DPM, FACFAS, D. Scot Malay, DPM, MSCE, FACFAS, Adam S. Landsman, DPM, Ph.D., FACFAS, Nathan Jennato, DPM, James Huish, DPM, and Melissa Younger, DPM.
Nextremity Solutions Inc. is a privately held developer of foot and ankle surgical technology. The company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.
The Nextra device is a two-piece implant developed by Nextremity Solutions Inc., a pure-play foot and ankle orthopedic device firm located in Warsaw, Ind. The product differs from K-wires by achieving more than a five-fold higher rate of bone fusion. Additionally, the Nextra implant exhibited an 84 percent fusion rate, compared to just 16 percent with K-wires.
“Some of the issues with the utilization of K-wires in hammertoe surgery are a lack of fusion, lack of rotational stability, risk of infection with post-operative K-Wire exposure, and poor patient satisfaction. According to the study, patients with the Nextra implant not only had drastic improvements in fusion rates but also experienced greater pain relief, a decrease in disability and an increase in activity levels. Simply put, the Nextra patients had greater patient satisfaction outcomes. These results help redefine the standard of care for hammertoe patients,” said Mike Coon, executive director of sales and marketing for Nextremity Solutions.
“This study is a great example of our commitment to proving the clinical efficacy and benefits of our products and technology. Nextremity Solutions will continue to work with our surgeon partners to develop innovative solutions with improved and proven clinical outcomes,” added Ryan Schlotterback, executive director of product development for Nextremity Solutions. “We are steadfast in our belief that the foot and ankle market is primed for continued advancements that lead to better surgical outcomes and patient satisfaction.”
The surgeons involved in the randomized controlled clinical trial are Richard M. Jay, DPM, FACFAS, D. Scot Malay, DPM, MSCE, FACFAS, Adam S. Landsman, DPM, Ph.D., FACFAS, Nathan Jennato, DPM, James Huish, DPM, and Melissa Younger, DPM.
Nextremity Solutions Inc. is a privately held developer of foot and ankle surgical technology. The company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.